Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia
This study has been terminated.
Information provided by:
First received: December 14, 2005
Last updated: March 28, 2007
Last verified: March 2007
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
Drug: MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
Drug: Placebo / Duration of Treatment: 2 days for screening period
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||MK0928 Phase II Sleep Laboratory Study - Primary Insomnia|
Further study details as provided by Merck:
Contacts and Locations